Tumor-associated antigen-expressing allogeneic tumor cell

Tumor-associated antigen-expressing allogeneic tumor cells are cancer cells sourced from individuals of the same species and selected for expressing antigens commonly found on tumors (but potentially also at low levels in normal tissues)[3][5][7]. These cells are used in immunotherapy as whole-cell vaccines, with the goal of educating a patient's immune system to recognize and attack cancer via exposure to a pool of tumor-associated antigens[1][6][8]. Allogeneic vaccines offer manufacturing and logistical advantages over autologous vaccines, such as ease of mass production and broader applicability, but are challenged by intra-tumoral heterogeneity and lack of patient specificity. The immunostimulatory potential is augmented by stimulating cells to upregulate danger and stress proteins before inactivation[6]; however, clinical trials have shown only limited success to date, and their optimal use likely lies as adjuvant therapies post-surgery or chemotherapy for targeting residual tumors[1][6][8]. This is not a specific molecular entity, but a cell-based modality leveraging the immunogenicity of shared tumor antigens.

Other names

Allogeneic tumor cell vaccineWhole-cell allogeneic cancer vaccineAllogeneic cancer cells"Zombie cell" vaccine (used in research context)

Induction of adaptive immune response through presentation of tumor-associated antigens (TAAs) Activation of T lymphocytes and cross-priming of cytotoxic responses Enhanced immunogenicity via inclusion of damage/stress-associated molecules (e.g., heat shock proteins)[6][1]